Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00388726
Status:
COMPLETED
Last Update Posted:
2020-01-07
First Post:
2006-10-13
Brief Title:
E7389 Versus Treatment of Physicians Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
The EMBRACE Trial Eisai Metastatic Breast Cancer Study Assessing Physicians Choice Versus E7389 A Phase III Open-Label Randomized Parallel Two-arm Multi-center Study of E7389 Versus Treatment of Physicians Choice in Patients With Locally Recurrent Metastatic Breast Cancer Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens Including an Anthracycline and a Taxane
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare Overall Survival OS Progression Free Survival PFS objective tumor response rate duration of response and safety in patients treated with E7389 versus the Treatment of Physicians Choice TPC in patients with locally recurrent or metastatic breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-001949-34 | EUDRACT_NUMBER | None | None |